Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802 | Director | June 16, 2022 | June 16, 2022 |
| OnKure Therapeutics, Inc.OKUR · Entity 6550 | Chief Medical Officer | August 07, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INFINITY PHARMACEUTICALS, INC.
Report date June 16, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2032-06-16 | Direct | 45,000 |
Reported balance
After 2022-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-16 · Grant · Acquired 45,000 · Balance 45,000 F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
OnKure Therapeutics, Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2036-08-06 | Direct | 50,000 |
Reported balance
After 2026-08-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 50,000 · Balance 50,000 F1: 1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.99 · Expires 2034-02-05 | Direct | 0 |
Reported balance
After 2026-08-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-07 · Disposition to issuer · Disposed 18,588 · Balance 0 F3: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2: 1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2034-02-05 | Direct | 18,588 |
Reported balance
After 2026-08-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-07 · Grant · Acquired 18,588 · Balance 18,588 F3: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2: 1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.20 · Expires 2034-10-03 | Direct | 0 |
Reported balance
After 2026-08-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-07 · Disposition to issuer · Disposed 131,396 · Balance 0 F3: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F5: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2034-10-03 | Direct | 131,396 |
Reported balance
After 2026-08-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-07 · Grant · Acquired 131,396 · Balance 131,396 F3: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F5: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2: 1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F3: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.
F4: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.
F5: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foghorn Therapeutics Inc.
Report date September 11, 2023 · Filed September 13, 2023
Section 16 reporting ended · disclosed 2023-09-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.63 · Expires 2031-01-27 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2023-09-11 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 100,000 F1: The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.87 · Expires 2032-01-25 | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2023-09-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 125,000 F2: The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2030-08-17 | Direct | 91,891 |
Reported balance
Holding disclosure · report date 2023-09-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 91,891 F3: The option vested as to 25% of the underlying shares of common stock on August 17, 2021, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.38 · Expires 2033-01-25 | Direct | 60,000 |
Reported balance
Holding disclosure · report date 2023-09-11 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 60,000 F4: The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested as to 25% of the underlying shares of common stock on January 28, 2022, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter.
F2: The option vested as to 25% of the underlying shares of common stock on January 26, 2023, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter.
F3: The option vested as to 25% of the underlying shares of common stock on August 17, 2021, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter.
F4: The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 11, 2026 20:23 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantEmployee Stock Option (right to buy) · Derivative | 131,396 | Not disclosed Strike: $4.14 | Not disclosed |
DisclosureSEC source: 0001748961-26-000002 · form4-08112026_080820.xml · derivative · entry 5 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,396 Underlying: Class A Common Stock · 131,396 shares Expires 2034-10-03 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F5 · derivative.exercise_date: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:23 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 131,396 | Not disclosed Strike: $18.20 | Not disclosed |
DisclosureSEC source: 0001748961-26-000002 · form4-08112026_080820.xml · derivative · entry 4 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 131,396 shares Expires 2034-10-03 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F5 · derivative.exercise_date: 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:23 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantEmployee Stock Option (right to buy) · Derivative | 18,588 | Not disclosed Strike: $4.14 | Not disclosed |
DisclosureSEC source: 0001748961-26-000002 · form4-08112026_080820.xml · derivative · entry 3 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,588 Underlying: Class A Common Stock · 18,588 shares Expires 2034-02-05 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2 · derivative.exercise_date: 1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:23 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 18,588 | Not disclosed Strike: $13.99 | Not disclosed |
DisclosureSEC source: 0001748961-26-000002 · form4-08112026_080820.xml · derivative · entry 2 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 18,588 shares Expires 2034-02-05 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date. F4 · price: Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options. F2 · derivative.exercise_date: 1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 20:23 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001748961-26-000002 · form4-08112026_080820.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 50,000 shares Expires 2036-08-06 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 19:25 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantEmployee Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001748961-26-000001 · form4-04032026_070420.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Class A Common Stock · 110,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| January 27, 2025 Filed Jan 30, 2025 01:33 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantEmployee Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001415889-25-002309 · form4-01302025_010108.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Stock · 45,000 shares Expires 2035-01-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 23:20 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantEmployee Stock Option (right to buy) · Derivative | 131,396 | $0.00 Strike: $18.20 | $0.00 |
DisclosureSEC source: 0001415889-24-024911 · form4-10082024_111019.xml · derivative · entry 2 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,396 Underlying: Class A Common Stock · 131,396 shares Expires 2034-10-03 F4 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 23:20 UTC | OnKure Therapeutics, Inc. OKUR · Entity 6550 | GrantEmployee Stock Option (right to buy) · Derivative | 18,588 | Not disclosed Strike: $13.99 | Not disclosed |
DisclosureSEC source: 0001415889-24-024911 · form4-10082024_111019.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,588 Underlying: Class A Common Stock · 18,588 shares Expires 2034-02-05 F2 · price: The Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR." Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, (footnote continued in footnote (3)) F3 · price: (continued from footnote (2)) a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:03 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionStock Option (right to buy) · Derivative | 311,297 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001562180-23-006433 · primarydocument.xml · derivative · entry 3 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 311,297 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on September 16, 2020, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until fully vested. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:03 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | SaleCommon Stock | 311,297 | $8.25 | $2,568,200.25 |
DisclosureSEC source: 0001562180-23-006433 · primarydocument.xml · nonDerivative · entry 2 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:03 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | Exercise / conversionCommon Stock | 311,297 | $3.72 | $1,158,024.84 |
DisclosureSEC source: 0001562180-23-006433 · primarydocument.xml · nonDerivative · entry 1 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 22:04 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001562180-23-000728 · primarydocument.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-01-25 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Read SEC document |
| June 16, 2022 Filed Jun 16, 2022 20:42 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option(right to buy) · Derivative | 45,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001140361-22-023318 · form4.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:27 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $14.87 | $0.00 |
DisclosureSEC source: 0001562180-22-000751 · primarydocument.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-25 F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares of common stock on January 26, 2023, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 16:16 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001140361-21-020649 · form4.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 02:26 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0000899243-21-003968 · doc4.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The options will vest as to 25% of the underlying shares of common stock on January 28, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested. Read SEC document |
| October 16, 2020 Filed Oct 16, 2019 19:18 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0000899243-19-025628 · doc4.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-10-16 F1 · derivative.exercise_date: The option vests as to 1/8th of the shares on December 31, 2019 and as to 1/8th of the shares at the end of each calendar quarter thereafter, provided that the holder continues to serve as a director of the Issuer. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 08:30 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0000899243-20-017000 · doc4.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 16:05 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 62,596 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0000899243-19-000654 · doc4.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,596 Underlying: Common Stock · 62,596 shares Expires 2029-01-04 F1 · derivative.exercise_date: The option vests as to 1/48th of the shares on January 31, 2019 and vests as to 1/48th of the shares at the end of each calendar month thereafter. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 17:10 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000899243-18-021568 · doc4.xml · derivative · entry 1 Agresta Samuel · CIK 0001748961 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-08-06 F1 · derivative.exercise_date: The option vests as to 12/48th of the shares on August 6, 2019 and vests as to 1/48th of the shares at the end of each calendar month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.